Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$485.42 USD

485.42
904,979

+3.15 (0.65%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (168 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bruker (BRKR) Gains From New Product Bookings Amid Competition

by Zacks Equity Research

Bruker's (BRKR) revenue recognition from one gigahertz class NMR system and continued uptake of the timsTOF platform hold promise.

    Walgreens Boots' (WBA) Product Expansion Aids Amid Rivalry

    by Zacks Equity Research

    Sales contributions from Walgreens Boots' (WBA) newly-formed Walgreens Health segment instill investors' optimism.

    Here's Why Investors Should Retain Amedisys (AMED) Stock for Now

    by Zacks Equity Research

    Investors are optimistic about Amedisys' (AMED) better-than-expected earnings and notable buyouts.

    PerkinElmer's (PKI) Reagent Kit Receives FDA Clearance

    by Zacks Equity Research

    PerkinElmer's (PKI) T-Cell Select reagent kit is expected to allow for a more automated workflow following the FDA's approval.

    Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?

    by Zacks Equity Research

    Smart Beta ETF report for FXG

    The Zacks Analyst Blog Highlights NextEra Energy, Southern Company, PepsiCo, Corteva and McKesson

    by Zacks Equity Research

    NextEra Energy, Southern Company, PepsiCo, Corteva and McKesson are included in this Analyst Blog.

    Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

    by Zacks Equity Research

    Investors are optimistic about QIAGEN's (QGEN) better-than-expected results and solid genomics uptake.

    Abbott (ABT) Reports Favorable Findings From RELIEF Study

    by Zacks Equity Research

    The latest data from the RELIEF Study suggests a lower rate of hospitalizations from serious diabetes-related events with Abbott's (ABT) FreeStyle Libre system.

    3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio

    by Zacks Equity Research

    NextGen's (NXGN) strong product portfolio and solid prospects in the RCM space raise optimism about the stock.

    Here's Why You Should Bet on ShockWave Medical (SWAV) Stock

    by Zacks Equity Research

    ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.

    Here's Why You Should Buy McKesson (MCK) Stock Right Now

    by Zacks Equity Research

    McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

    Medtronic (MDT) Gets FDA's 510(k) Nod for Pediatric ICM

    by Zacks Equity Research

    This latest approval broadens Medtronic's scope within its Cardiovascular Diagnostics and Services wing within broader Cardiovascular business.

    Nalak Das headshot

    Bet on These 5 Ultra-Defensive Stocks for the Rest of 2022

    by Nalak Das

    We have narrowed our search to five low-beta high-yielding defensive stocks that have strong potential for the rest of 2022. These are: NEE, SO, PEP, CTVA and MCK.

    Charles River (CRL) Gains From Growing Demand Amid Macro Woes

    by Zacks Equity Research

    Charles River (CRL) continues to expect that the growth rate will approach 20% in the second half of 2022.

    McKesson (MCK) Stock Pares Gains Following Rx Savings Buyout

    by Zacks Equity Research

    McKesson (MCK) agrees to buy privately-held Rx Savings Solutions in alignment with its strategic plan of creating accessible and affordable treatment options.

    Here's Why You Should Retain Stryker (SYK) Stock For Now

    by Zacks Equity Research

    Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.

    Zimmer Biomet (ZBH) to Offer New Shoulder Replacement System

    by Zacks Equity Research

    Zimmer Biomet (ZBH) gets FDA nod for the Identity Shoulder System to help surgeons perform anatomic, reverse and revision shoulder replacement with precision.

    Abiomed (ABMD) Posts Impellas Positive Study Results in Japan

    by Zacks Equity Research

    Abiomed's (ABMD) latest multi-center, multi-society study of Impella-supported patients is expected to significantly improve patient outcomes.

    3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio

    by Zacks Equity Research

    PacBio's (PACB) strength in its Sequel system raises optimism about the stock.

    Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?

    by Zacks Equity Research

    Sector ETF report for FXG

    McKesson (MCK) Stock Moves -0.97%: What You Should Know

    by Zacks Equity Research

    McKesson (MCK) closed the most recent trading day at $345.56, moving -0.97% from the previous trading session.

    Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

    by Zacks Equity Research

    Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Higher production costs are a woe.

    Quest Diagnostics (DGX) to Offer Lab Services for Lee Health

    by Zacks Equity Research

    Quest Diagnostics (DGX) inked a new agreement to deliver high-quality diagnostics services for a renowned healthcare provider in Southwest Florida.

    Here's Why You Should Retain Boston Scientific (BSX) For Now

    by Zacks Equity Research

    Investors are optimistic about Boston Scientific's (BSX) impressive top-line results and notable acquisitions.

    Inari Medical (NARI) Posts Positive Results of FLASH Registry

    by Zacks Equity Research

    Inari Medical's (NARI) FlowTriever's latest favorable results are expected to significantly improve the treatment of PE.